The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor Is Necessary in the Development of Arteriosclerosis by Recruiting/Activating Monocytes in a Rat Model of Long-Term Inhibition of Nitric Oxide Synthesis
Abstract
Background — It remains unclear whether vascular endothelial growth factor (VEGF) is a proarteriosclerotic or an antiarteriosclerotic factor. We recently reported that long-term inhibition of nitric oxide by administering Nω -nitro- l -arginine methyl ester (L-NAME) induces coronary vascular inflammation and arteriosclerosis. Methods and Results — We used this animal model to investigate the role of VEGF in arteriosclerosis. We blocked VEGF activity in vivo by transfecting with plasmid DNA encoding the murine soluble FLT-1 ( sFLT-1 ) gene into thigh muscle. Soluble FLT-1 can suppress VEGF activity both by sequestering VEGF and by functioning as a dominant-negative inhibitor of VEGF receptors. We observed vascular inflammation associated with increased VEGF expression within 3 days of L-NAME administration, which was prevented by pretreatment with ACE inhibitor, angiotensin II receptor antagonist, or neutralizing monocyte chemoattractant protein-1 antibody. The sFLT-1 gene transfer attenuated the early vascular inflammation and prevented late arteriosclerosis. The sFLT-1 gene transfer also inhibited increased expression of monocyte chemoattractant protein-1 and transforming growth factor-β, indicating creation of a positive feedback loop to cause arteriosclerosis. Conclusions — VEGF is necessary in the development of arteriosclerosis by mediating monocyte recruitment and activation in this model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A concern regarding VEGF use is increased local inflammation because cell migration and proliferation also correlate with angiogenesis.200–201”
From Biocompatible Materials for Continuous Glucose Monitoring Devices (2013) · cites this paper as [200]
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Barleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marmé, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,350
Kim, I., Moon, S.-O., Kim, S. H., Kim, H. J., Koh, Y. S., & Koh, G. Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009705200 · Cited by 768
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 744
Kendall, R. L., Wang, G., & Thomas, K. A. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1355 · Cited by 734
Vascular endothelial growth factor enhances atherosclerotic plaque progression
Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R., & Dake, M. D. (2001) · Nature Medicine · doi:10.1038/86490 · Cited by 708
Hernández-Presa, M. Á., Bustos, C., Ortego, M., Tuñon, J., Renedo, G., Ruiz‐Ortega, M., & Egido, J. (1997) · Circulation · doi:10.1161/01.cir.95.6.1532 · Cited by 494
BELLE, E. V., Witzenbichler, B., Chen, D., Silver, M., Chang, L., SCHWALL, R. H., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.4.381 · Cited by 443
Reciprocal relation between VEGF and NO in the regulation of endothelial integrity
Tsurumi, Y., Murohara, T., Krasinski, K. L., Chen, D., Witzenbichler, B., Kearney, M., Couffinhal, T., & Isner, J. M. (1997) · Nature Medicine · doi:10.1038/nm0897-879 · Cited by 357
Takemoto, M., Egashira, K., Usui, M., Numaguchi, K., Tomita, H., Tsutsui, H., Shimokawa, H., Sueishi, K., & Takeshita, A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119156 · Cited by 322
Self-citation
Cited by
Sorted by citations
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson, L. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,083
Self-citationRole of Angiogenesis in Cardiovascular Disease
Khurana, R., Simons, M., Martin, J. F., & Zachary, I. C. (2005) · Circulation · doi:10.1161/circulationaha.105.535294 · Cited by 459
Angiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401
Diabetic Endothelial Nitric Oxide Synthase Knockout Mice Develop Advanced Diabetic Nephropathy
Nakagawa, T., Sato, W., Glushakova, O. Y., Heinig, M., Clarke, T., Campbell‐Thompson, M., Yuzawa, Y., Atkinson, M. A., Johnson, R. J., & Croker, B. P. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050459 · Cited by 370
Metadata
- Authors
- Zhao, Q., Egashira, K., Inoue, S., Usui, M., Kitamoto, S., Ni, W., Ishibashi, M., Hiasa, K.-I., Ichiki, T., Shibuya, M., & Takeshita, A.
- Affiliations
- Kyushu University (JP)
- ORCID
- Venue
- Circulation
- Published
- 2002-03-05
- Volume
- 105
- Issue
- 9
- Pages
- 1110-1115
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2159600810
- Cited by
- 136
- References
- 20
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 2
- FWCI
- 11.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- vascular endothelial growth factor, arteriosclerosis, nitric oxide inhibition, L-NAME, soluble Flt-1, monocyte recruitment, monocyte activation, vascular inflammation, MCP-1, TGF-beta, ACE inhibitors, angiotensin receptor blockers, gene transfer, coronary arteries
- MeSH terms
- Animals, Arteriosclerosis, Biological Assay, Blood Pressure, Cell Division, Chemotaxis, Leukocyte, Coronary Vessels, Disease Models, Animal, Enzyme Inhibitors, Genetic Vectors, Inflammation, Injections, Intramuscular, Peptidyl-Dipeptidase A, Lymphokines, Male, Monocytes, Nitric Oxide, Proto-Oncogene Proteins, Rats, Inbred WKY, RNA, Messenger, Time, Gene Expression, Transforming Growth Factor beta, Endothelial Growth Factors, Neovascularization, Physiologic, Chemokine CCL2, NG-Nitroarginine Methyl Ester, Receptor Protein-Tyrosine Kinases, Gene Transfer, Horizontal, Vascular Endothelial Growth Factor Receptor-1, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
